Research across borders

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find studies Explore world registries Peptide directory

Find a study

Enter a peptide, product, condition or location. Try generic names, brand names and development codes separately. Results are registry search matches, not automatically verified links to a WPF peptide record.

Search terms are sent to ClinicalTrials.gov and appear in the page URL. Do not enter personal or medical identifying information. Registry records are served with up to a one-hour cache; registry updates themselves can lag real-world changes.

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 19:08 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableCompletedINTERVENTIONAL

Does Nicotine Influence the Risk of Preeclampsia?

ClinicalTrials.gov · NCT06645340 · Registry updated: 2024-10-23

Condition / research focus: Preeclampsia (PE); Endothelial Dysfunction; Hypertension in Pregnancy
Sponsor: Medical University of Graz
Countries with listed sites: Austria
Registry dates and results: Start: 2019-11-02. Completion: 2023-12-17 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length (other)

Where the study takes place — 1 listed sites

Site status can differ from overall study status. This list includes all reported sites, even when your search specifies one location. Confirm availability and eligibility with the study team through the original record.

Medical University Graz
Graz, Styria, Austria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19

ClinicalTrials.gov · NCT05218356 · Registry updated: 2024-10-02

Condition / research focus: COVID-19
Sponsor: Code Pharma
Countries with listed sites: Brazil
Registry dates and results: Start: 2022-01-20. Completion: 2025-07-20 (may be estimated). No results posted in this registry response.

Products and interventions (9)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Covidir injections (drug) — also listed as: Experimental drug administration
Quantitative PCR SARS-CoV-2 (diagnostic_test)
IgM and IgG dosage (diagnostic_test)
Screening Blood tests (diagnostic_test)
Electrocardiogram (diagnostic_test) — also listed as: ECG
NEWS-2 score (other)
WHO score (other)
Physical examination (other)
COVID-19-Related Symptoms assessment (other)

Where the study takes place — 5 listed sites

Hospital de Amor
Paulo Prata, Barretos/SP/BRA, Brazil
Site recruitment: Recruiting
Infection Control
Prado, Belo Horizonte/MG/BRA, Brazil
Site recruitment: Recruiting
Instituto Lobus
Casa de Pedra, Volta Redonda/RJ/BRA, Brazil
Site recruitment: Recruiting
A2Z Clinical
Vila Martina, Volta Redonda/RJ/BRA, Brazil
Site recruitment: Recruiting
Casa de Saude
Centro, Brazil
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Measuring Immune Tolerance to Predict Miscarriage or Failed Embryo Transfer

ClinicalTrials.gov · NCT04156126 · Registry updated: 2024-09-25

Condition / research focus: Infertility; Pregnancy Loss; Spontaneous Abortion
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2019-08-23. Completion: 2024-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Blood Collection (other)

Where the study takes place — 1 listed sites

Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Effect of HCG on Endometrial Preparation in Frozen Embryo Transfer

ClinicalTrials.gov · NCT06577181 · Registry updated: 2024-09-19

Condition / research focus: IVF
Sponsor: Assiut University
Countries with listed sites: Egypt
Registry dates and results: Start: 2024-05-10. Completion: 2026-05-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

hCG + estradiol (drug)
Observation arm (other)

Where the study takes place — 1 listed sites

Assiut university
Asyut, Asyut Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)

ClinicalTrials.gov · NCT00703014 · Registry updated: 2024-09-19

Condition / research focus: Pregnancy; Neonates
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-07-13. Completion: 2009-03-15 (may be estimated). Results are posted in this registry.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin Alfa 150 μg (drug)
200 IU RecFSH/Follitropin beta (Days 1 to 7) (biological) — also listed as: follitropin beta, Puregon®, Follistim®
Placebo for Corifollitropin Alfa (drug)
Placebo for RecFSH/Follitropin beta (drug)
200 IU RecFSH/Follitropin beta (Days 8 to hCG) (biological)
Ganirelix (drug)
hCG (biological)
Progesterone (biological)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)

ClinicalTrials.gov · NCT00702273 · Registry updated: 2024-09-05

Condition / research focus: In Vitro Fertilization
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-04-19. Completion: 2009-05-31 (may be estimated). Results are posted in this registry.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

150 µg Corifollitropin Alfa (drug)
200 IU RecFSH/Follitropin beta (Days 1 to 7) (biological)
Placebo for Corifollitropin Alfa (drug)
Placebo for RecFSH/Follitropin beta (drug)
200 IU RecFSH/Follitropin beta (Days 8 to hCG) (biological)
Ganirelix (drug)
hCG (biological)
Progesterone (biological)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)

ClinicalTrials.gov · NCT00702338 · Registry updated: 2024-09-05

Condition / research focus: Pregnancy; Neonates
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2008-05-15. Completion: 2008-12-15 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

corifollitropin alfa (drug) — also listed as: Org 36286, MK-8962, SCH 900962
recombinant Follicle Stimulating Hormone (recFSH) (biological)
human Chorion Gonadotropin (hCG) (biological)
hCG Bolus injection (biological)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)

ClinicalTrials.gov · NCT00702520 · Registry updated: 2024-09-05

Condition / research focus: Pregnancy; Neonates
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-04-01. Completion: 2008-01-15 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alpha (MK-8962, Org 36286) 100 ug (drug)
Corifollitropin alpha (MK-8962, Org 36286) 150 ug (drug)
Triptorelin (drug)
Recombinant follicle stimulating hormone (recFSH) (biological)
Human chorionic gonadotprophin (hCG). (biological)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)

ClinicalTrials.gov · NCT00702234 · Registry updated: 2024-09-05

Condition / research focus: Pregnancy; Neonates
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2007-02-15. Completion: 2010-01-15 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (biological) — also listed as: Org 36286, SCH 900962, MK-8962
GnRH antagonist (biological)
(rec)hCG (biological)
FSH (biological)
Progesterone (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Frozen-thawed Embryo Transfer in a Natural Cycle: hCG Triggering Versus LH Home Test

ClinicalTrials.gov · NCT03115320 · Registry updated: 2024-08-22

Condition / research focus: Infertility
Sponsor: Tampere University Hospital
Countries with listed sites: Finland
Registry dates and results: Start: 2017-01. Completion: 2019-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Human chorionic gonadotropin (drug) — also listed as: Home ovulation test
Home ovulation test (other)

Where the study takes place — 1 listed sites

Tampere University Hospital
Tampere, Finland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection

ClinicalTrials.gov · NCT06561594 · Registry updated: 2024-08-20

Condition / research focus: Idiopathic Hypogonadotropic Hypogonadism
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-09-20. Completion: 2026-12-23 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant human follicle-stimulating hormone-CTP Fusion protein injection (drug)
recombinant human follicle-stimulating hormone-CTP Fusion protein injection Placebo (drug)

Where the study takes place — 17 listed sites

Anhui Children's Hospital
Hefei, Anhui, China
Site recruitment: Not reported
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking Union Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Site recruitment: Not reported
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Women and Children's Medical Center Affiliated to Guangzhou Medical University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Shenzhen Children's Hospital
Shenzhen, Guangdong, China
Site recruitment: Not reported
Henan Children's Hospital Zhengzhou Children's Hospital
Zhengzhou, Henan, China
Site recruitment: Not reported
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Site recruitment: Not reported
Nanjing Children's Hospital
Nanjing, Jiangsu, China
Site recruitment: Not reported
Jiangxi Children's Hospital
Nanchang, Jiangxi, China
Site recruitment: Not reported
Shengjing Hospital affiliated to China Medical University
Shenyang, Liaoning, China
Site recruitment: Not reported
Affiliated Hospital of Jining Medical College
Jining, Shangdong, China
Site recruitment: Not reported
Shanghai Children's Hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Affiliated Pediatric Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Chengdu Women and Children's Central Hospital
Chengdu, Sichuan, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)

ClinicalTrials.gov · NCT00702806 · Registry updated: 2024-08-15

Condition / research focus: Infertility; In Vitro Fertilization
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2001-07-01. Completion: 2002-10-15 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Org 36286 (drug) — also listed as: Corifollitropin alpha
Puregon® (drug) — also listed as: recFSH
Orgalutran® (drug) — also listed as: ganirelix (Ganirelix Acetate Injection)
Pregnyl® (drug) — also listed as: human chorionic gonadatropin, hCG

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phase II Clinical Trials of Org 36286 (Study 38817)(P06054)(COMPLETED)

ClinicalTrials.gov · NCT00702195 · Registry updated: 2024-08-15

Condition / research focus: Pregnancy
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2002-01-01. Completion: 2003-09-15 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Org 36286 (corifollitropin alfa) (drug) — also listed as: corifollitropin alfa
Placebo (drug)
recFSH (drug) — also listed as: follitropin beta, Puregon®, Follistim®

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016)

ClinicalTrials.gov · NCT00702585 · Registry updated: 2024-08-15

Condition / research focus: Infertility
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2001-08-01. Completion: 2002-10-15 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Org 36286 (drug) — also listed as: Corifollitropin alpha
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)

ClinicalTrials.gov · NCT00598208 · Registry updated: 2024-08-15

Condition / research focus: Fertilization
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2003-05-19. Completion: 2004-03-15 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

corifollitropin alfa (drug) — also listed as: Org 36286
Follitropin beta injection (drug) — also listed as: Follistim®, Puregon®

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1TerminatedINTERVENTIONAL

Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia

ClinicalTrials.gov · NCT02353143 · Registry updated: 2024-08-12

Condition / research focus: Recurrent Adult Acute Myeloid Leukemia; Acute Myeloid Leukemia, in Relapse
Sponsor: Menarini Group
Countries with listed sites: Belgium · France · Germany · Italy · Spain
Registry dates and results: Start: 2014-12. Completion: 2021-04-09 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

MEN1112 (drug)

Where the study takes place — 29 listed sites

Facility not reported
Antwerp, Belgium
Site recruitment: Not reported
Facility not reported
Brussels, Belgium
Site recruitment: Not reported
Facility not reported
Liège, Belgium
Site recruitment: Not reported
Facility not reported
Roeselare, Belgium
Site recruitment: Not reported
Facility not reported
Yvoir, Belgium
Site recruitment: Not reported
Facility not reported
Grenoble, France
Site recruitment: Not reported
Facility not reported
Lille, France
Site recruitment: Not reported
Facility not reported
Lyon, France
Site recruitment: Not reported
Facility not reported
Marseille, France
Site recruitment: Not reported
Facility not reported
Nantes, France
Site recruitment: Not reported
Facility not reported
Paris, France
Site recruitment: Not reported
Facility not reported
Pierre-Bénite, France
Site recruitment: Not reported
Facility not reported
Toulouse, France
Site recruitment: Not reported
Facility not reported
Villejuif, France
Site recruitment: Not reported
Facility not reported
Dresden, Germany
Site recruitment: Not reported
Facility not reported
Essen, Germany
Site recruitment: Not reported
Facility not reported
Frankfurt, Germany
Site recruitment: Not reported
Facility not reported
Munich, Germany
Site recruitment: Not reported
Facility not reported
Bologna, Italy
Site recruitment: Not reported
Facility not reported
Brescia, Italy
Site recruitment: Not reported
Facility not reported
Milan, Italy
Site recruitment: Not reported
Facility not reported
Rome, Italy
Site recruitment: Not reported
Facility not reported
Torino, Italy
Site recruitment: Not reported
Facility not reported
Badalona, Spain
Site recruitment: Not reported
Facility not reported
Barcelona, Spain
Site recruitment: Not reported
Facility not reported
Pamplona, Spain
Site recruitment: Not reported
Facility not reported
Salamanca, Spain
Site recruitment: Not reported
Facility not reported
Seville, Spain
Site recruitment: Not reported
Facility not reported
Valencia, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

An Open Labeled RCT on the Effect of Additional hCG Injection for LPS on Pregnancy Outcomes in IHH Patients

ClinicalTrials.gov · NCT05569577 · Registry updated: 2024-08-07

Condition / research focus: Luteal Phase Deficiency; Luteal Phase Support; Idiopathic Hypogonadotropic Hypogonadism
Sponsor: Fudan University
Countries with listed sites: China
Registry dates and results: Start: 2021-01-01. Completion: 2025-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Additional hCG injection (drug)
estrogen and dydrogesterone (drug)

Where the study takes place — 2 listed sites

OB & GYN Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Recruiting
Obstetrics and Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

GDF-8 Levels in ICSI Cycles

ClinicalTrials.gov · NCT06529627 · Registry updated: 2024-07-31

Condition / research focus: Infertility
Sponsor: University of Alexandria
Countries with listed sites: Egypt
Registry dates and results: Start: 2023-05-01. Completion: 2024-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Long Gn-RH agonist protocol - Intracytoplasmic Sperm Injection (procedure)

Where the study takes place — 1 listed sites

Shatby maternity university hospital
Alexandria, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Investigational Oocyte Cryopreservation for Medical and Non Medical Indications

ClinicalTrials.gov · NCT04616417 · Registry updated: 2024-07-30

Condition / research focus: Infertility, Female; Deferred Childbearing
Sponsor: University of Illinois Chicago
Countries with listed sites: United States
Registry dates and results: Start: 2015-05-08. Completion: 2023-03-20 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Investigational Oocyte Cryopreservation (procedure)

Where the study takes place — 1 listed sites

University of Illinois Hospital & Health Sciences System - IVF Program in the Fertility Center
Chicago, Illinois, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Natural Cycle vs. Modified Natural Cycle vs. Artificial Cycle Protocol for Endometrial Preparation.

ClinicalTrials.gov · NCT04804020 · Registry updated: 2024-07-29

Condition / research focus: IVF; Frozen Embryo Transfer
Sponsor: Mỹ Đức Hospital
Countries with listed sites: Vietnam
Registry dates and results: Start: 2021-03-22. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NC (procedure)
mNC (procedure)
AC (procedure)

Where the study takes place — 1 listed sites

My Duc Hospital
Ho Chi Minh City, Vietnam
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Explore the world’s study registries

These links open external registries; their records are not merged into the results above. WHO ICTRP provides a broader search across contributing registries. Search the same generic name, aliases and development codes in relevant regions. One multinational study may appear in more than one registry, so compare registration identifiers before counting it twice.

Worldwide

Africa

Pan African Clinical Trial Registry ↗

Americas

Asia

Middle East

Europe

Oceania

Australia / New Zealand — ANZCTR ↗

Registry directory checked October 5, 2026 against the WHO registry network. This is a starting point, not complete coverage of every country or continent. Record availability, language and update schedules vary by registry.

Worldwide Study Finder

Loading registry information…

Worldwide Study Finder

Where are peptides being studied? Explore registered human studies by product, phase, condition and location — from early development through Phase 4, alongside studies where phase does not apply.

Searchable results come from ClinicalTrials.gov and include international sites. For broader coverage, use the worldwide and regional registries below. No single registry captures every study.

Find a study

Registry search results

Matching records; showing 20 on this page, newest registry updates first. Search checked 2026-11-08 19:08 UTC. Counts are registry matches, not unique peptides or a worldwide total.

Not applicableCompletedINTERVENTIONAL

Does Nicotine Influence the Risk of Preeclampsia?

ClinicalTrials.gov · NCT06645340 · Registry updated: 2024-10-23

Condition / research focus: Preeclampsia (PE); Endothelial Dysfunction; Hypertension in Pregnancy
Sponsor: Medical University of Graz
Countries with listed sites: Austria
Registry dates and results: Start: 2019-11-02. Completion: 2023-12-17 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

This high-risk cohort underwent the same measurements during pregnancy: endothelial function, arterial stiffness, retinal microvasculature profile, measurement of Neprilysin, cotinine, telomere length (other)

Where the study takes place — 1 listed sites

Medical University Graz
Graz, Styria, Austria
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2UnknownINTERVENTIONAL

Phase IIa Randomized Placebo Controlled Clinical Study of Codivir in Hospitalized Patients with Moderate COVID-19

ClinicalTrials.gov · NCT05218356 · Registry updated: 2024-10-02

Condition / research focus: COVID-19
Sponsor: Code Pharma
Countries with listed sites: Brazil
Registry dates and results: Start: 2022-01-20. Completion: 2025-07-20 (may be estimated). No results posted in this registry response.

Products and interventions (9)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Covidir injections (drug) — also listed as: Experimental drug administration
Quantitative PCR SARS-CoV-2 (diagnostic_test)
IgM and IgG dosage (diagnostic_test)
Screening Blood tests (diagnostic_test)
Electrocardiogram (diagnostic_test) — also listed as: ECG
NEWS-2 score (other)
WHO score (other)
Physical examination (other)
COVID-19-Related Symptoms assessment (other)

Where the study takes place — 5 listed sites

Hospital de Amor
Paulo Prata, Barretos/SP/BRA, Brazil
Site recruitment: Recruiting
Infection Control
Prado, Belo Horizonte/MG/BRA, Brazil
Site recruitment: Recruiting
Instituto Lobus
Casa de Pedra, Volta Redonda/RJ/BRA, Brazil
Site recruitment: Recruiting
A2Z Clinical
Vila Martina, Volta Redonda/RJ/BRA, Brazil
Site recruitment: Recruiting
Casa de Saude
Centro, Brazil
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Measuring Immune Tolerance to Predict Miscarriage or Failed Embryo Transfer

ClinicalTrials.gov · NCT04156126 · Registry updated: 2024-09-25

Condition / research focus: Infertility; Pregnancy Loss; Spontaneous Abortion
Sponsor: Mayo Clinic
Countries with listed sites: United States
Registry dates and results: Start: 2019-08-23. Completion: 2024-06-01 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Blood Collection (other)

Where the study takes place — 1 listed sites

Mayo Clinic
Rochester, Minnesota, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableUnknownOBSERVATIONAL

Effect of HCG on Endometrial Preparation in Frozen Embryo Transfer

ClinicalTrials.gov · NCT06577181 · Registry updated: 2024-09-19

Condition / research focus: IVF
Sponsor: Assiut University
Countries with listed sites: Egypt
Registry dates and results: Start: 2024-05-10. Completion: 2026-05-10 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

hCG + estradiol (drug)
Observation arm (other)

Where the study takes place — 1 listed sites

Assiut university
Asyut, Asyut Governorate, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05787 (P05712)

ClinicalTrials.gov · NCT00703014 · Registry updated: 2024-09-19

Condition / research focus: Pregnancy; Neonates
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-07-13. Completion: 2009-03-15 (may be estimated). Results are posted in this registry.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin Alfa 150 μg (drug)
200 IU RecFSH/Follitropin beta (Days 1 to 7) (biological) — also listed as: follitropin beta, Puregon®, Follistim®
Placebo for Corifollitropin Alfa (drug)
Placebo for RecFSH/Follitropin beta (drug)
200 IU RecFSH/Follitropin beta (Days 8 to hCG) (biological)
Ganirelix (drug)
hCG (biological)
Progesterone (biological)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Follow-up Study of Frozen-thawed Embryo Transfer (FTET) Cycles After Cryopreservation of Embryos in Clinical Trial P05787 (P05716)

ClinicalTrials.gov · NCT00702273 · Registry updated: 2024-09-05

Condition / research focus: In Vitro Fertilization
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-04-19. Completion: 2009-05-31 (may be estimated). Results are posted in this registry.

Products and interventions (8)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

150 µg Corifollitropin Alfa (drug)
200 IU RecFSH/Follitropin beta (Days 1 to 7) (biological)
Placebo for Corifollitropin Alfa (drug)
Placebo for RecFSH/Follitropin beta (drug)
200 IU RecFSH/Follitropin beta (Days 8 to hCG) (biological)
Ganirelix (drug)
hCG (biological)
Progesterone (biological)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05693 (P05713)

ClinicalTrials.gov · NCT00702338 · Registry updated: 2024-09-05

Condition / research focus: Pregnancy; Neonates
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2008-05-15. Completion: 2008-12-15 (may be estimated). Results are posted in this registry.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

corifollitropin alfa (drug) — also listed as: Org 36286, MK-8962, SCH 900962
recombinant Follicle Stimulating Hormone (recFSH) (biological)
human Chorion Gonadotropin (hCG) (biological)
hCG Bolus injection (biological)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)

ClinicalTrials.gov · NCT00702520 · Registry updated: 2024-09-05

Condition / research focus: Pregnancy; Neonates
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2006-04-01. Completion: 2008-01-15 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alpha (MK-8962, Org 36286) 100 ug (drug)
Corifollitropin alpha (MK-8962, Org 36286) 150 ug (drug)
Triptorelin (drug)
Recombinant follicle stimulating hormone (recFSH) (biological)
Human chorionic gonadotprophin (hCG). (biological)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715)

ClinicalTrials.gov · NCT00702234 · Registry updated: 2024-09-05

Condition / research focus: Pregnancy; Neonates
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2007-02-15. Completion: 2010-01-15 (may be estimated). Results are posted in this registry.

Products and interventions (5)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Corifollitropin alfa (biological) — also listed as: Org 36286, SCH 900962, MK-8962
GnRH antagonist (biological)
(rec)hCG (biological)
FSH (biological)
Progesterone (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 4TerminatedINTERVENTIONAL

Frozen-thawed Embryo Transfer in a Natural Cycle: hCG Triggering Versus LH Home Test

ClinicalTrials.gov · NCT03115320 · Registry updated: 2024-08-22

Condition / research focus: Infertility
Sponsor: Tampere University Hospital
Countries with listed sites: Finland
Registry dates and results: Start: 2017-01. Completion: 2019-12 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Human chorionic gonadotropin (drug) — also listed as: Home ovulation test
Home ovulation test (other)

Where the study takes place — 1 listed sites

Tampere University Hospital
Tampere, Finland
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 3Not yet recruitingINTERVENTIONAL

To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection

ClinicalTrials.gov · NCT06561594 · Registry updated: 2024-08-20

Condition / research focus: Idiopathic Hypogonadotropic Hypogonadism
Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.
Countries with listed sites: China
Registry dates and results: Start: 2024-09-20. Completion: 2026-12-23 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

recombinant human follicle-stimulating hormone-CTP Fusion protein injection (drug)
recombinant human follicle-stimulating hormone-CTP Fusion protein injection Placebo (drug)

Where the study takes place — 17 listed sites

Anhui Children's Hospital
Hefei, Anhui, China
Site recruitment: Not reported
Beijing Children's Hospital, Capital Medical University
Beijing, Beijing Municipality, China
Site recruitment: Not reported
Peking Union Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China
Site recruitment: Not reported
The First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Women and Children's Medical Center Affiliated to Guangzhou Medical University
Guangzhou, Guangdong, China
Site recruitment: Not reported
Shenzhen Children's Hospital
Shenzhen, Guangdong, China
Site recruitment: Not reported
Henan Children's Hospital Zhengzhou Children's Hospital
Zhengzhou, Henan, China
Site recruitment: Not reported
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Site recruitment: Not reported
Nanjing Children's Hospital
Nanjing, Jiangsu, China
Site recruitment: Not reported
Jiangxi Children's Hospital
Nanchang, Jiangxi, China
Site recruitment: Not reported
Shengjing Hospital affiliated to China Medical University
Shenyang, Liaoning, China
Site recruitment: Not reported
Affiliated Hospital of Jining Medical College
Jining, Shangdong, China
Site recruitment: Not reported
Shanghai Children's Hospital
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Affiliated Pediatric Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Not reported
Chengdu Women and Children's Central Hospital
Chengdu, Sichuan, China
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Investigate Dose of Org 36286 to Initiate Multiple Follicular Growth in a Controlled Ovarian Hyperstimulation Protocol for IVF or IVF/ICSI (P07015)

ClinicalTrials.gov · NCT00702806 · Registry updated: 2024-08-15

Condition / research focus: Infertility; In Vitro Fertilization
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2001-07-01. Completion: 2002-10-15 (may be estimated). No results posted in this registry response.

Products and interventions (4)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Org 36286 (drug) — also listed as: Corifollitropin alpha
Puregon® (drug) — also listed as: recFSH
Orgalutran® (drug) — also listed as: ganirelix (Ganirelix Acetate Injection)
Pregnyl® (drug) — also listed as: human chorionic gonadatropin, hCG

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase not reported / not applicableCompletedOBSERVATIONAL

Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established During Phase II Clinical Trials of Org 36286 (Study 38817)(P06054)(COMPLETED)

ClinicalTrials.gov · NCT00702195 · Registry updated: 2024-08-15

Condition / research focus: Pregnancy
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2002-01-01. Completion: 2003-09-15 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Org 36286 (corifollitropin alfa) (drug) — also listed as: corifollitropin alfa
Placebo (drug)
recFSH (drug) — also listed as: follitropin beta, Puregon®, Follistim®

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

Study to Investigate the Optimal Dose of Org 36286 to Induce Monofollicular Ovulation in Women With WHO Group II Anovulatory Infertility (P07016)

ClinicalTrials.gov · NCT00702585 · Registry updated: 2024-08-15

Condition / research focus: Infertility
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2001-08-01. Completion: 2002-10-15 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Org 36286 (drug) — also listed as: Corifollitropin alpha
Placebo (drug)

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 2CompletedINTERVENTIONAL

A Phase 2, Trial to Investigate the Dose-Response Relationship of a Single Injection of Org 36286 (Corifollitropin Alfa) to Initiate Multiple Follicular Growth in a Controlled Ovarian (Study 38826)(P06055)(COMPLETED)

ClinicalTrials.gov · NCT00598208 · Registry updated: 2024-08-15

Condition / research focus: Fertilization
Sponsor: Organon and Co
Countries with listed sites: No country reported
Registry dates and results: Start: 2003-05-19. Completion: 2004-03-15 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

corifollitropin alfa (drug) — also listed as: Org 36286
Follitropin beta injection (drug) — also listed as: Follistim®, Puregon®

Where the study takes place — 0 listed sites

The registry does not list facilities in this record. This does not mean the study has no sites.

Original record, eligibility, contacts and results →

Phase 1TerminatedINTERVENTIONAL

Study of MEN1112 Intravenous Infusion in Relapsed or Refractory Acute Myeloid Leukemia

ClinicalTrials.gov · NCT02353143 · Registry updated: 2024-08-12

Condition / research focus: Recurrent Adult Acute Myeloid Leukemia; Acute Myeloid Leukemia, in Relapse
Sponsor: Menarini Group
Countries with listed sites: Belgium · France · Germany · Italy · Spain
Registry dates and results: Start: 2014-12. Completion: 2021-04-09 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

MEN1112 (drug)

Where the study takes place — 29 listed sites

Facility not reported
Antwerp, Belgium
Site recruitment: Not reported
Facility not reported
Brussels, Belgium
Site recruitment: Not reported
Facility not reported
Liège, Belgium
Site recruitment: Not reported
Facility not reported
Roeselare, Belgium
Site recruitment: Not reported
Facility not reported
Yvoir, Belgium
Site recruitment: Not reported
Facility not reported
Grenoble, France
Site recruitment: Not reported
Facility not reported
Lille, France
Site recruitment: Not reported
Facility not reported
Lyon, France
Site recruitment: Not reported
Facility not reported
Marseille, France
Site recruitment: Not reported
Facility not reported
Nantes, France
Site recruitment: Not reported
Facility not reported
Paris, France
Site recruitment: Not reported
Facility not reported
Pierre-Bénite, France
Site recruitment: Not reported
Facility not reported
Toulouse, France
Site recruitment: Not reported
Facility not reported
Villejuif, France
Site recruitment: Not reported
Facility not reported
Dresden, Germany
Site recruitment: Not reported
Facility not reported
Essen, Germany
Site recruitment: Not reported
Facility not reported
Frankfurt, Germany
Site recruitment: Not reported
Facility not reported
Munich, Germany
Site recruitment: Not reported
Facility not reported
Bologna, Italy
Site recruitment: Not reported
Facility not reported
Brescia, Italy
Site recruitment: Not reported
Facility not reported
Milan, Italy
Site recruitment: Not reported
Facility not reported
Rome, Italy
Site recruitment: Not reported
Facility not reported
Torino, Italy
Site recruitment: Not reported
Facility not reported
Badalona, Spain
Site recruitment: Not reported
Facility not reported
Barcelona, Spain
Site recruitment: Not reported
Facility not reported
Pamplona, Spain
Site recruitment: Not reported
Facility not reported
Salamanca, Spain
Site recruitment: Not reported
Facility not reported
Seville, Spain
Site recruitment: Not reported
Facility not reported
Valencia, Spain
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableUnknownINTERVENTIONAL

An Open Labeled RCT on the Effect of Additional hCG Injection for LPS on Pregnancy Outcomes in IHH Patients

ClinicalTrials.gov · NCT05569577 · Registry updated: 2024-08-07

Condition / research focus: Luteal Phase Deficiency; Luteal Phase Support; Idiopathic Hypogonadotropic Hypogonadism
Sponsor: Fudan University
Countries with listed sites: China
Registry dates and results: Start: 2021-01-01. Completion: 2025-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (2)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Additional hCG injection (drug)
estrogen and dydrogesterone (drug)

Where the study takes place — 2 listed sites

OB & GYN Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Recruiting
Obstetrics and Gynecology Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Site recruitment: Recruiting

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

GDF-8 Levels in ICSI Cycles

ClinicalTrials.gov · NCT06529627 · Registry updated: 2024-07-31

Condition / research focus: Infertility
Sponsor: University of Alexandria
Countries with listed sites: Egypt
Registry dates and results: Start: 2023-05-01. Completion: 2024-01-31 (may be estimated). No results posted in this registry response.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Long Gn-RH agonist protocol - Intracytoplasmic Sperm Injection (procedure)

Where the study takes place — 1 listed sites

Shatby maternity university hospital
Alexandria, Egypt
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Investigational Oocyte Cryopreservation for Medical and Non Medical Indications

ClinicalTrials.gov · NCT04616417 · Registry updated: 2024-07-30

Condition / research focus: Infertility, Female; Deferred Childbearing
Sponsor: University of Illinois Chicago
Countries with listed sites: United States
Registry dates and results: Start: 2015-05-08. Completion: 2023-03-20 (may be estimated). Results are posted in this registry.

Products and interventions (1)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

Investigational Oocyte Cryopreservation (procedure)

Where the study takes place — 1 listed sites

University of Illinois Hospital & Health Sciences System - IVF Program in the Fertility Center
Chicago, Illinois, United States
Site recruitment: Not reported

Original record, eligibility, contacts and results →

Not applicableCompletedINTERVENTIONAL

Natural Cycle vs. Modified Natural Cycle vs. Artificial Cycle Protocol for Endometrial Preparation.

ClinicalTrials.gov · NCT04804020 · Registry updated: 2024-07-29

Condition / research focus: IVF; Frozen Embryo Transfer
Sponsor: Mỹ Đức Hospital
Countries with listed sites: Vietnam
Registry dates and results: Start: 2021-03-22. Completion: 2023-12-31 (may be estimated). No results posted in this registry response.

Products and interventions (3)

Includes comparators and combinations. A search match is not a verified peptide identity or evidence of benefit.

NC (procedure)
mNC (procedure)
AC (procedure)

Where the study takes place — 1 listed sites

My Duc Hospital
Ho Chi Minh City, Vietnam
Site recruitment: Not reported

Original record, eligibility, contacts and results →